CalciMedica’s Auxora reduces D-Dimer levels in Covid-19 trial

Targeting Calcium Overload Could Improve Stroke Outcomes

A Journey: Biotech, FDA, and Safety Committee Responses to COVID

Dr. Hebbar of CalciMedica Talks Auxora Clinical Trial Targeting COVID-19, CRAC, and More| Podcast S2 E36

Companies To Watch: CalciMedica

Scroll to Top